Cross-sectional Survey on Clinical Practice and Pharmaceutical Care of Teicoplanin

OBJECTIVE Teicoplanin is a glycopeptide antibiotic used to treat severe infections caused by Gram-positive bacteria. Through the analysis of monitoring data of drug use in inpatients, this paper optimizes pharmaceutical care and provides a method for rational use of teicoplanin in clinical practice. METHODS The cross-sectional survey was designed to collect the clinical data of 183 inpatients treated with teicoplanin in China-Japan Friendship Hospital in 2018 January 1-December 31. RESULTS One hundred and eighty-three cases were finally included in this study and the administration of teicoplanin in 71.58% cases were for the treatment of pulmonary infection. Ninety-seven patients(53.01%) were given loading dosage in the initial treatment. The maintained regimen was 0.4 g qd(32.24%). There were 35 patients(19.13%) monitored the serum trough concentration of teicoplanin for 40 times. The average plasma trough concentration was (7.77±4.31)mg·L^-1. There were only 11 cases of plasma trough concentration >10 mg·L^-1, accounting for 27.50% of the total cases. There was a tendency that the average plasma trough concentration under different maintenance doses increased with the increase of dosage, but there was no significant difference(P=0.122). CONCLUSION The overall treatment dose of teicoplanin in hospitalized patients is insufficient. Most of the plasma trough concentration did not reach the target concentration. These problems may be the main reason why there was no significant change in infectious markers before and after administration in survey.